Casdin Capital’s Cardiff Oncology CRDF Stock Holding History

Casdin Capital’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-972	Closed	-$378K	–	30
2015 Q4	$378K	Buy	+972	New	+$381K	0.33%	29

Other funds holding CRDF

Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

MWVC

Morgens Waterfall Vintiadis & Co New York $131M AUM 101.21% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Casdin Capital's CRDF Position: Q1 2016 in Review

Casdin Capital sold out of Cardiff Oncology (CRDF) in Q1 2016, closing a stake of 972 shares — an estimated $378K sold.

Casdin Capital first reported a position in CRDF in Q4 2015 and held it in 1 quarter. The position peaked at $378K in Q4 2015. 58 funds tracked by Wall St. Rank hold CRDF as of Q1 2016.

Casdin Capital reported no remaining Cardiff Oncology position as of Q1 2016 after selling out during the quarter.
Casdin Capital sold 972 Cardiff Oncology shares in Q1 2016, an estimated $378K.
Casdin Capital first reported a position in Cardiff Oncology in Q4 2015 and held it in 1 quarter.
Casdin Capital's Cardiff Oncology position peaked at $378K in Q4 2015.
58 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2016.

Based on Casdin Capital's 13F filing for Q1 2016, filed 9 May 2016.